Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00279565
Recruitment Status :
(The trial was terminated because of deviations from the protocol.)
This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.
Condition or disease
Hepatitis C, Chronic
Drug: buprenorphineDrug: methadoneDrug: pegylated interferon alfa-2b plus ribavirin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female patients with a history of intravenous drug abuse, who are willing to undergo methadone or buprenorphine substitution.
Patients with newly diagnosed chronic hepatitis C.
Hepatitis C virus (HCV)-ribonucleic acid (RNA) positive in serum as measured by polymerase chain reaction (PCR) within the last 4 weeks.
Genotype 2 or 3.
Elevated alanine aminotransferase (ALT) levels.
In women of child-bearing age, pregnancy must be excluded prior to entry into the study, and the use of a safe contraceptive device (intrauterine device, oral contraceptive, diaphragm + spermicide, condom + spermicide, tubal ligation) must be documented.
Hemoglobin: >=12 g/dL (women) or >=13 g/dL (men)
Prothrombin time (PT)/partial thromboplastin time (PTT)/coagulation within the normal range
Albumin: not more than 10% deviation from lower normal value
Thyroid-stimulating hormone (TSH) normal
Uric acid normal
Antinuclear antibodies <=1:160
Signed informed consent.
Refusal by women of child-bearing age or by sexually active patients to use a safe contraceptive.
Cirrhosis stage B and C according to Child-Pugh.
Signs of decompensated liver disease (ascites, bleeding varices and spontaneous encephalopathy).
Confirmed co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV).
Existing psychiatric comorbidity.
Active malignant disease or suspicion or history of malignant disease within five previous years (except for adequately treated basal cell carcinoma).
Existing psoriasis or other dermatological disorder (relative exclusion criterion: due to great differences with regard to the severity of the disorder and the individual therapy compatibility, the therapy decision is at the discretion of the physician).
Treatment with a study drug within the last 30 days.
Any uncontrolled underlying medical conditions (e.g. diabetes).
Clinically significant electrocardiogram (ECG) abnormalities and / or significant cardiovascular dysfunction within the last 6 months (angina, heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia) is an exclusion criterion. In case of other suspected heart disease, a cardiologic examination is required prior to inclusion of the patient.
Any liver disorder of other genesis than the study indication (with regard to elevated iron levels, only patients with manifest hemochromatosis are excluded).
Autoimmune disorder (except LKM-positive patients: these patients may be included in the study).